Affinity Asset Advisors LLC Sells 47,390 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Affinity Asset Advisors LLC decreased its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 10.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 425,000 shares of the company's stock after selling 47,390 shares during the period. NewAmsterdam Pharma comprises about 1.5% of Affinity Asset Advisors LLC's investment portfolio, making the stock its 22nd biggest holding. Affinity Asset Advisors LLC owned 0.46% of NewAmsterdam Pharma worth $10,922,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in NewAmsterdam Pharma by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company's stock worth $1,433,000 after acquiring an additional 1,399 shares during the last quarter. National Bank of Canada FI bought a new position in NewAmsterdam Pharma in the fourth quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in NewAmsterdam Pharma during the fourth quarter worth $80,000. Legal & General Group Plc raised its stake in shares of NewAmsterdam Pharma by 24.8% in the 4th quarter. Legal & General Group Plc now owns 22,946 shares of the company's stock valued at $590,000 after buying an additional 4,556 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at $154,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Scotiabank upped their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. Needham & Company LLC restated a "buy" rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, April 8th. HC Wainwright reaffirmed a "buy" rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Finally, UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a report on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $43.33.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock traded up $0.31 on Friday, reaching $16.34. 277,248 shares of the stock were exchanged, compared to its average volume of 588,909. The firm's 50 day moving average is $19.87 and its 200-day moving average is $21.24. The firm has a market cap of $1.79 billion, a PE ratio of -6.28 and a beta of -0.01. NewAmsterdam Pharma has a one year low of $14.06 and a one year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to the consensus estimate of $3.30 million. On average, equities research analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director James N. Topper bought 1,135 shares of NewAmsterdam Pharma stock in a transaction that occurred on Wednesday, March 26th. The shares were acquired at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the acquisition, the director now directly owns 3,013,569 shares of the company's stock, valued at approximately $67,775,166.81. The trade was a 0.04 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the transaction, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. The trade was a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.